FDA orders class-wide GLP-1 anesthesia warning and approves first label change for Ozempic
The FDA has required GLP-1 drug labels to carry a warning about pulmonary aspiration during general anesthesia or deep sedation, and Ozempic is the first product whose revised label has been approved.
The Food and Drug Administration has directed makers of GLP-1 receptor agonist drugs to add a warning about a serious anesthesia-related risk to their product labeling, and the first revised label has been approved for Ozempic (semaglutide) injection [1].
In a letter dated September 6, 2024, the agency notified Novo Nordisk under Section 505(o)(4) of the Food, Drug, and Cosmetic Act of new safety information that it determined should be included in the labeling for glucagon-like peptide-1 receptor agonist (GLP-1 RA) products. According to the approval letter, that information concerns "the serious risk of pulmonary aspiration for patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation" [1].
Novo Nordisk submitted a supplemental new drug application for Ozempic on October 4, 2024, which was followed by email correspondence with the agency on October 11 and 16, 2024 [1]. The FDA approved the supplement, effective on the date of the approval letter, which carries an electronic signature dated November 1, 2024 [1].
The approved revisions add a section titled "Pulmonary Aspiration During General Anesthesia or Deep Sedation" to Section 6, Adverse Reactions, of the Ozempic prescribing information. The letter notes minor editorial changes, including margin marks to flag recent major changes and removal of italics from the new section heading [1]. A previously granted waiver of the half-page length requirement for the Highlights section of the prescribing information remains in place [1].
The approval letter sets several deadlines. Novo Nordisk must submit the content of labeling in structured product labeling format within 14 days of the letter, and the content must be identical to the enclosed prescribing information, Medication Guide and Instructions for Use [1]. The company must also amend pending supplemental applications that include labeling changes for this drug within the same 14 days [1]. Promotional materials that mention the product must be promptly revised to include "prominent disclosure of the important new safety-related information" in the revised labeling, and the company must submit a statement of intent to comply within 7 days of receiving the letter [1]. The agency said the supplement is exempt from required pediatric assessments because it does not involve a new active ingredient, indication, dosage form, dosing regimen or route of administration [1].
Why it matters for patients
The labeling change means the anesthesia-related risk is now part of the prescribing information that clinicians and anesthesiologists read, and it is the first GLP-1 product label confirmed in this document to carry it [1]. Anyone taking Ozempic who is scheduled for an elective surgery or procedure involving general anesthesia or deep sedation may now encounter this warning in the product's official labeling or in the material their care team reviews. The notification described the risk as serious but did not explain how it was identified, nor did it set out steps for patients to take before a procedure [1].
What happens next
The letter gives Novo Nordisk 7 days to state its intent to comply with the promotional-labeling requirements and 14 days to file the content of labeling in structured product labeling format; both periods run from the date of the approval letter [1]. Whether other manufacturers of GLP-1 receptor agonist products have received similar notifications or updated their labels has not been disclosed in this document [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.